Asenapine 5-20 mg daily + Placebo 1-4 tablets daily
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Major Depressive Disorder Without Psychotic Features
Conditions
Major Depressive Disorder Without Psychotic Features
Trial Timeline
Oct 1, 2012 → Jun 1, 2014
NCT ID
NCT01670019About Asenapine 5-20 mg daily + Placebo 1-4 tablets daily
Asenapine 5-20 mg daily + Placebo 1-4 tablets daily is a approved stage product being developed by Merck for Major Depressive Disorder Without Psychotic Features. The current trial status is completed. This product is registered under clinical trial identifier NCT01670019. Target conditions include Major Depressive Disorder Without Psychotic Features.
What happened to similar drugs?
20 of 20 similar drugs in Major Depressive Disorder Without Psychotic Features were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01670019 | Approved | Completed |
Competing Products
20 competing products in Major Depressive Disorder Without Psychotic Features
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 26 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 29 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 40 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 43 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 42 |
| LY2216684 + Sertraline | Eli Lilly | Phase 1 | 29 |
| LY2216684 + Placebo + Lorazepam | Eli Lilly | Phase 1 | 29 |
| LY2216684 + SSRI | Eli Lilly | Phase 3 | 40 |